Compare LI & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | WST |
|---|---|---|
| Founded | 2015 | 1923 |
| Country | China | United States |
| Employees | 30728 | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 18.5B |
| IPO Year | N/A | 2004 |
| Metric | LI | WST |
|---|---|---|
| Price | $16.63 | $304.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.66 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.7M | 927.7K |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.92 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $18.98 | $6.76 |
| Revenue Next Year | $22.72 | $6.22 |
| P/E Ratio | ★ $29.50 | $158.44 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $15.71 | $203.74 |
| 52 Week High | $32.03 | $330.88 |
| Indicator | LI | WST |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 57.64 |
| Support Level | $16.30 | $259.17 |
| Resistance Level | $19.04 | $321.34 |
| Average True Range (ATR) | 0.49 | 8.89 |
| MACD | -0.04 | -2.40 |
| Stochastic Oscillator | 2.95 | 32.54 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.